{"brief_title": "Evaluation of the Effect of Pramlintide on Satiety and Food Intake", "brief_summary": "This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.", "condition": ["Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Pramlintide acetate", "Placebo"], "description": ["Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.", "placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper"], "arm_group_label": ["Pramlintide", "Placebo"], "criteria": "For Healthy Volunteers: \u2022BMI >=20 to <=25kg/m2 or >=30 to <=40 kg/m2 For Subjects with Type 1 or Type 2 Diabetes: - Treated with insulin for at least 6 months prior to screening - HbA1c value between 6.5-10% inclusive - BMI between 20-40kg/m2", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Diabetes Mellitus, Type 1", "Pramlintide", "Islet Amyloid Polypeptide"], "id": "NCT00042601"}